Evidence map›Paper›PMID 33199757›Full record

ArticleScientific reports2020

Tetrahydrobiopterin prevents chronic ischemia-related lower urinary tract dysfunction through the maintenance of nitric oxide bioavailability.

Hidenori Akaihata, Junya Hata, Ryo Tanji, Ruriko Honda-Takinami, Kanako Matsuoka, Yuichi Sato, Masao Kataoka, Soichiro Ogawa, Yoshiyuki Kojima

Abstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hidenori AkaihataDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan. hidenoriakaihata@yahoo.co.jp.
Junya HataDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Ryo TanjiDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Ruriko Honda-TakinamiDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Kanako MatsuokaDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Yuichi SatoDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Masao KataokaDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Soichiro OgawaDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.
Yoshiyuki KojimaDepartment of Urology, Fukushima Medical University of School of Medicine, Fukushima, 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to investigate the influence of chronic ischemia on nitric oxide biosynthesis in the bladder and the effect of administering tetrahydrobiopterin (BH4), a cofactor for endothelial nitric oxide synthase (eNOS), on chronic ischemia-related lower urinary tract dysfunction (LUTD). This study divided male Sprague-Dawley rats into Control, chronic bladder ischemia (CBI) and CBI with oral BH4 supplementation (CBI/BH4) groups. In the CBI group, bladder capacity and bladder muscle strip contractility were significantly lower, and arterial wall was significantly thicker than in Controls. Significant improvements were seen in bladder capacity, muscle strip contractility and arterial wall thickening in the CBI/BH4 group as compared with the CBI group. Western blot analysis of bladder showed expressions of eNOS (p = 0.043), HIF-1α (p < 0.01) and dihydrofolate reductase (DHFR) (p < 0.01), which could regenerate BH4, were significantly higher in the CBI group than in Controls. In the CBI/BH4 group, HIF-1α (p = 0.012) and DHFR expressions (p = 0.018) were significantly decreased compared with the CBI group. Our results suggest that chronic ischemia increases eNOS and DHFR in the bladder to prevent atherosclerosis progression. However, DHFR could not synthesize sufficient BH4 relative to the increased eNOS, resulting in LUTD. BH4 supplementation protects lower urinary tract function by promoting eNOS activity.

Indexed as

AnimalsBiological AvailabilityBiopterinsGene Expression RegulationHypoxia-Inducible Factor 1, alpha SubunitIschemiaMaleMuscle ContractionNitric OxideNitric Oxide Synthase Type IIIOxidation-ReductionRatsRats, Sprague-DawleyTetrahydrofolate DehydrogenaseUrinary BladderBiopterinsHif1a protein, ratHypoxia-Inducible Factor 1, alpha SubunitNitric OxideNitric Oxide Synthase Type IIINos3 protein, ratsapropterinTetrahydrofolate Dehydrogenase

Identifiers

PMID33199757
PMCPMC7670448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.